These results suggest that AICAR might also be a potential therapeutic intervention to prevent statin myopathies associated with RyR1 mutations in sensitive individuals and protect against myopathies arising from high statin doses in individuals without RyR1 mutations. The gene discussed is RYR1; the disease is myopathy.